Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $53.00

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been given an average rating of "Buy" by the nine brokerages that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $53.00.

DNTH has been the subject of several recent analyst reports. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Guggenheim reiterated a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. SG Americas Securities LLC boosted its holdings in Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock valued at $210,000 after acquiring an additional 814 shares during the last quarter. KBC Group NV bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $35,000. R Squared Ltd bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $26,000. Rhumbline Advisers boosted its holdings in Dianthus Therapeutics by 3.8% in the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company's stock valued at $783,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock valued at $3,641,000 after buying an additional 1,092 shares during the period. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded down $0.49 during trading hours on Monday, hitting $17.93. The stock had a trading volume of 296,301 shares, compared to its average volume of 273,818. The company has a market capitalization of $576.63 million, a P/E ratio of -7.17 and a beta of 1.48. The firm's 50-day moving average price is $19.04 and its two-hundred day moving average price is $21.62. Dianthus Therapeutics has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.81 million. As a group, analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.